Search
Silodosin
go.drugbank.com/drugs/DB06207ApprovedInvestigational[A231159] Silodosin works by binding to α<sub>1A</sub>-adrenoceptors with high affinity and relaxing the lower urinary tract, thereby improving urinary symptoms and alleviating bladder outlet obstruction … [A231159] Silodosin was first approved by the FDA in October 2008 [A231159] and it is also approved in Europe and Canada.
Bictegravir
go.drugbank.com/drugs/DB11799ApprovedInvestigationalBictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet.
Poliovirus type 1 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10795ApprovedInvestigationaltype 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by
Mixtures: Td Polio Adsorbed, PENTAXİM 0,5 ML IM ENJEKSİYONLUK SÜSPANSİYON İÇİN TOZ İÇEREN FLAKON VE SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETPoliovirus type 3 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10797ApprovedInvestigationaltype 3 antigen is a suspension of poliovirus Type 3 (Saukett) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by
Mixtures: Td Polio Adsorbed, PENTAXİM 0,5 ML IM ENJEKSİYONLUK SÜSPANSİYON İÇİN TOZ İÇEREN FLAKON VE SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETTamsulosin
go.drugbank.com/drugs/DB00706ApprovedInvestigational[A178351] Tamsulosin was first approved by the FDA on April 15, 1997.[L6238] … [Label] Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor muscles in the bladder, allowing for better urinary flow.
Mixtures: Duoride-T 0.5mg/0.4mg CapsulesFruquintinib
go.drugbank.com/drugs/DB11679ApprovedInvestigational[A262102,A262107] Indeed, oncogenic activation, loss of tumor suppressor function, and hypoxia, usually facilitated by cancer cells, are known to upregulate VEGF. … The first approach can be exemplified by [bevacizumab], a VEGF-A trap antibody.
Lotilaner
go.drugbank.com/drugs/DB17992ApprovedInvestigationalVet approved[A260746, L47556] Lotilaner consists of two enantiomers: the S-enantiomer is active _in vivo_, while the R-enantiomer is reported to exhibit low biological activity. … [A260741] On July 25, 2023, lotilaner was approved by the FDA for the treatment of Demodex blepharitis, making it the first and only approved therapeutic for this condition.[L47551]
Baricitinib
go.drugbank.com/drugs/DB11817ApprovedInvestigational[L41760] Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and was later approved by the FDA in 2018. … By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses.
Alverine
go.drugbank.com/drugs/DB01616ApprovedInvestigationalWithdrawnIt can also be used to help relieve period pain. … Alverine is a smooth muscle relaxant used to relieve cramps or spasms of the stomach and intestines. It is therefore useful in treating irritable bowel syndrome (IBS) and similar conditions.
Tadalafil
go.drugbank.com/drugs/DB00820ApprovedInvestigational[L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. … In contrast to other PDE5 inhibitors like [sildenafil], tadalafil has greater selectivity for PDE5 and a longer half-life which has made it a more suitable option for chronic once-daily dosing in the treatment